Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA (GLORI)
Primary Purpose
Clostridium Difficile
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Universal gloving
Sponsored by
About this trial
This is an interventional health services research trial for Clostridium Difficile focused on measuring Clostridium difficile, Barrier Precautions, Personal Protective Equipment
Eligibility Criteria
Inclusion Criteria:
VA inpatient units meeting the following criteria are eligible to participate in the study:
Ability to identify one of the following inpatient units as defined by CDC National Healthcare Safety Network30 by reviewing prior 12-month patient mix data (at least 80% of patients meet patient type):
- Adult Acute Medical Ward: Hospital area for the evaluation and treatment of patients with medical conditions or disorders.
- Adult Acute Medical/Surgical Ward: Hospital area for the evaluation of patients with medical and/or surgical conditions.
- Adult Acute Surgical Ward: Hospital area for evaluation and treatment of patients who have undergone a surgical procedure.
- Ability to collect and upload data (HAIs, mortality, length of stay, hand hygiene and barrier precaution compliance; glove use and glove plus gown use for contact precautions) required for analysis.
- Local R&D Committee approval.
- Letter of support from the Hospital Director or Chief of Staff.
- Ability to be matched with another hospital unit based on baseline C. difficile acquisition rates meeting minimal threshold to detect change in C. difficile rate.
To participate in interviews or focus groups, the individual must be:
- 18 years of age or older
- A patient admitted to the participating unit OR a healthcare worker who has regular work duties on the participating unit.
Exclusion Criteria:
- Intensive care units
- Long term care units
- Mixed-acuity units
- Specialty units
Sites / Locations
- Washington DC VA Medical Center, Washington, DCRecruiting
- Edward Hines Jr. VA Hospital, Hines, ILRecruiting
- James J. Peters VA Medical Center, Bronx, NYRecruiting
- VA Portland Health Care System, Portland, ORRecruiting
- William S. Middleton Memorial Veterans Hospital, Madison, WI
- Clement J. Zablocki VA Medical Center, Milwaukee, WIRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention
Control
Arm Description
Enact universal gloving practices
Continue standard of care gloving practices
Outcomes
Primary Outcome Measures
C. difficile acquisition rates
Acquisition will be defined as a patient who has an initial stool culture upon unit admission that is negative for C. difficile and the patient's subsequent discharge culture within the same unit that is positive for C. difficile. Acquisition rate will be (# of acquisitions/patient days)
Secondary Outcome Measures
Hospital-onset C. difficile infection (HO-CDI) rates
The development of CDI as determined by the presence of clinical symptoms and positive laboratory results. Infection rates will be measured on the unit level. Infection rate will be (# of CDI/patient days)
CLABSI (HAI) rates
The rates of healthcare-associated central line-associated bloodstream infection (CLABSI) will be measured as (# of CLABSI cases per number of device days) on the unit level.
30-day mortality rate
Patients' average 30-day mortality (percentage of patients that died within 30 days after unit admission date) will be measured on the unit level.
Intervention fidelity - barrier precaution compliance
Healthcare worker barrier precaution compliance with unit-wide gloving practices during patient care activities will be measured via observations in participating units. Compliance will be measured as a percentage of use of appropriate gloving practices per opportunities for gloving practices.
Length of stay
Patient's average length of stay (number of days spent in the hospital based on unit admission and discharge) will be measured on the unit level.
HAI Cost
Estimated costs of burden caused by healthcare-associated infections based on published reports
CAUTI (HAI) rates
The rates of healthcare-associated catheter-associated urinary tract infection (CAUTI) will be measured as (# of CAUTI cases per number of device days) on the unit level.
MRSA (HAI) rates
The rates of healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) infection will be measured as (# of MRSA cases/patient days) on the unit level.
Patient and Healthcare Worker Experience
Qualitative interviews of patients and healthcare workers evalutaing their experience with the intervention; universal gloving
Supply Costs
Estimated based on glove use data, collected from a monthly list of supplies (i.e. gloves) issued to each unit (both control and intervention arms) from their distribution departments.
Full Information
NCT ID
NCT04036058
First Posted
July 24, 2019
Last Updated
October 10, 2023
Sponsor
VA Office of Research and Development
Collaborators
University of Wisconsin, Madison
1. Study Identification
Unique Protocol Identification Number
NCT04036058
Brief Title
Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA
Acronym
GLORI
Official Title
Effect of Expanding Barrier Precautions for Reducing Clostridium Difficile Acquisition in VA
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 29, 2022 (Actual)
Primary Completion Date
December 29, 2023 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development
Collaborators
University of Wisconsin, Madison
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Clostridium difficile (C. difficile) is a major pathogen causing serious healthcare-associated diarrheal illness in patients. Prevention of healthcare facility-onset C. difficile infection (CDI) is essential. Many CDI cases are caused by the transmission of the pathogen from patients who carry the bacteria, but do not have symptoms. However, there are limited data on how to prevent the transmission of C. difficile from patients who do not have symptoms. Universal gloving practices - the use of gloves by all healthcare workers for all patient contacts - may reduce CDI cases. In this study, the investigators will examine the effectiveness of universal gloving practices as compared to standard of care (use of gloving for contact only in patients with known CDI or other infections). The investigators will compare the effects of these practices on the transmission of C. difficile within participating hospital units to determine if universal gloving is an effective practice to prevent healthcare-associated CDI.
Detailed Description
Background: Clostridium difficile infection (CDI) has become the most common healthcare-associated infection (HAI) in US hospitals, causing approximately 500,000 infections and 30,000 deaths per year. Prevention of healthcare-onset (HO) CDI has quickly become a priority for many hospitals. Hospital prevention measures are limited to modifiable risk factors (i.e., prudent antibiotic use and limiting exposure to C. difficile). Hospital exposure to C. difficile can occur directly (i.e., hands or clothing of healthcare workers) or indirectly (i.e., environmental surfaces or shared equipment), so infection prevention measures focus on healthcare worker hand hygiene, barrier precautions (use of gowns and gloves) and cleaning of the hospital environment and reusable medical equipment. However, these interventions are limited to symptomatic patients who test positive for CDI. Asymptomatic patients serve as a reservoir for cross-contamination, but microbiological screening for asymptomatic carriage of C. difficile is not routinely performed in healthcare. Gloving for all patient contacts may interrupt transmission from asymptomatic patients colonized with C. difficile.
Objectives: The overall purpose of the study is to determine the effectiveness of healthcare worker use of gloves for all patient contact (universal gloving) on reducing acquisition of C. difficile and hospital-onset CDI in inpatient hospital units. The main objective of the study is to compare the effects of universal gloving for all patient contact to the current standard of care (i.e., glove and gown use only for known CDI cases). The specific aims are: 1) compare the effects of universal gloving for all patient contact to the current standard of care on C. difficile acquisition rates in hospitalized patients; 2) compare the effects of universal gloving compared to standard of care on CDI rates, other HAI rates, 30-day mortality, and unit length of stay; and 3) evaluate intervention fidelity, cost, and stakeholder experiences with universal gloving.
Methods: The study will be a cluster randomized trial (CRT) in ten inpatient VA hospital units. Hospital units will be randomized either to implement universal gloving intervention or to continue standard of care. The universal gloving intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing gloves for all patient contacts in the units that are randomized to receive the intervention. The non-intervention units will follow standard of care which consists of healthcare workers using gowns and gloves only for patients with known CDI and other infections (e.g., MRSA). Unit-level data will be collected, including C. difficile acquisition and infection rates, mortality, length of stay, barrier precaution compliance, and end-user perceptions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clostridium Difficile
Keywords
Clostridium difficile, Barrier Precautions, Personal Protective Equipment
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Two-arm parallel assignment: the 10 participating units will be randomized; at each site, one unit will be randomized to the intervention group and one unit to the control group so that 5 units will enact the universal gloving intervention and 5 units will continue standard of care gloving practices.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Enact universal gloving practices
Arm Title
Control
Arm Type
No Intervention
Arm Description
Continue standard of care gloving practices
Intervention Type
Other
Intervention Name(s)
Universal gloving
Other Intervention Name(s)
Expanded barrier precautions
Intervention Description
The intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing universal gloving (non-sterile gloves) for all patient contacts in the units that are randomized to receive the intervention. If a patient in the intervention unit is known to have CDI or a multidrug-resistant organisms, both gowns and gloves will be used as is currently recommended. Signage denoting what type of precautions are needed will be utilized.
Primary Outcome Measure Information:
Title
C. difficile acquisition rates
Description
Acquisition will be defined as a patient who has an initial stool culture upon unit admission that is negative for C. difficile and the patient's subsequent discharge culture within the same unit that is positive for C. difficile. Acquisition rate will be (# of acquisitions/patient days)
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Hospital-onset C. difficile infection (HO-CDI) rates
Description
The development of CDI as determined by the presence of clinical symptoms and positive laboratory results. Infection rates will be measured on the unit level. Infection rate will be (# of CDI/patient days)
Time Frame
12 months
Title
CLABSI (HAI) rates
Description
The rates of healthcare-associated central line-associated bloodstream infection (CLABSI) will be measured as (# of CLABSI cases per number of device days) on the unit level.
Time Frame
12 months
Title
30-day mortality rate
Description
Patients' average 30-day mortality (percentage of patients that died within 30 days after unit admission date) will be measured on the unit level.
Time Frame
12 months
Title
Intervention fidelity - barrier precaution compliance
Description
Healthcare worker barrier precaution compliance with unit-wide gloving practices during patient care activities will be measured via observations in participating units. Compliance will be measured as a percentage of use of appropriate gloving practices per opportunities for gloving practices.
Time Frame
12 months
Title
Length of stay
Description
Patient's average length of stay (number of days spent in the hospital based on unit admission and discharge) will be measured on the unit level.
Time Frame
12 months
Title
HAI Cost
Description
Estimated costs of burden caused by healthcare-associated infections based on published reports
Time Frame
12 months
Title
CAUTI (HAI) rates
Description
The rates of healthcare-associated catheter-associated urinary tract infection (CAUTI) will be measured as (# of CAUTI cases per number of device days) on the unit level.
Time Frame
12 months
Title
MRSA (HAI) rates
Description
The rates of healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) infection will be measured as (# of MRSA cases/patient days) on the unit level.
Time Frame
12 months
Title
Patient and Healthcare Worker Experience
Description
Qualitative interviews of patients and healthcare workers evalutaing their experience with the intervention; universal gloving
Time Frame
12 months
Title
Supply Costs
Description
Estimated based on glove use data, collected from a monthly list of supplies (i.e. gloves) issued to each unit (both control and intervention arms) from their distribution departments.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
VA inpatient units meeting the following criteria are eligible to participate in the study:
Ability to identify one of the following inpatient units as defined by CDC National Healthcare Safety Network30 by reviewing prior 12-month patient mix data (at least 80% of patients meet patient type):
Adult Acute Medical Ward: Hospital area for the evaluation and treatment of patients with medical conditions or disorders.
Adult Acute Medical/Surgical Ward: Hospital area for the evaluation of patients with medical and/or surgical conditions.
Adult Acute Surgical Ward: Hospital area for evaluation and treatment of patients who have undergone a surgical procedure.
Ability to collect and upload data (HAIs, mortality, length of stay, hand hygiene and barrier precaution compliance; glove use and glove plus gown use for contact precautions) required for analysis.
Local R&D Committee approval.
Letter of support from the Hospital Director or Chief of Staff.
Ability to enroll one unit to intervention and one unit to control.
To participate in interviews or focus groups, the individual must be:
18 years of age or older
A patient admitted to the participating unit OR a healthcare worker who has regular work duties on the participating unit.
Exclusion Criteria:
Intensive care units
Long term care units
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nasia Safdar, MD PhD
Phone
(608) 280-7007
Email
Nasia.Safdar@va.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Linda L McKinley, BSN MPH
Phone
(608) 256-1901
Ext
11776
Email
Linda.Mckinley2@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nasia Safdar, MD PhD
Organizational Affiliation
William S. Middleton Memorial Veterans Hospital, Madison, WI
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington DC VA Medical Center, Washington, DC
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20422-0001
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amy Weintrob
Email
Amy.Weintrob@va.gov
First Name & Middle Initial & Last Name & Degree
Amy Weintrob
Facility Name
Edward Hines Jr. VA Hospital, Hines, IL
City
Hines
State/Province
Illinois
ZIP/Postal Code
60141-3030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cara Ray
Phone
(708) 202-4558
Email
Cara.Ray@va.gov
First Name & Middle Initial & Last Name & Degree
Charlesnika T Evans, PhD MPH BS
Phone
(708) 202-8387
Ext
24868
Email
charlesnika.evans@va.gov
First Name & Middle Initial & Last Name & Degree
Charlesnika Tyon Evans, PhD MPH BS
Facility Name
James J. Peters VA Medical Center, Bronx, NY
City
Bronx
State/Province
New York
ZIP/Postal Code
10468-3904
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael A Gelman, MD PhD AB
Phone
718-584-9000
Ext
6680
Email
Michael.Gelman@va.gov
First Name & Middle Initial & Last Name & Degree
Michael A Gelman, MD PhD AB
Facility Name
VA Portland Health Care System, Portland, OR
City
Portland
State/Province
Oregon
ZIP/Postal Code
97207-2964
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christopher D Pfeiffer, MD MHS
Phone
503-220-8262
Ext
58127
Email
Christopher.Pfeiffer2@va.gov
First Name & Middle Initial & Last Name & Degree
Christopher D. Pfeiffer, MD MHS
Facility Name
William S. Middleton Memorial Veterans Hospital, Madison, WI
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705-2254
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Clement J. Zablocki VA Medical Center, Milwaukee, WI
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53295-0001
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gaylyn A Raduenz
Phone
414-384-2000
Ext
47156
Email
Gaylyn.Raduenz@va.gov
First Name & Middle Initial & Last Name & Degree
Florine Ndakuya-Fitzgerald
First Name & Middle Initial & Last Name & Degree
Mary E Hagle, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA
We'll reach out to this number within 24 hrs